ASLN

ASLAN Pharmaceuticals
ASLN

$0.70
37.84%

Market Cap: 1.98M

 

About: ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment.

Employees: 35

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.32% less ownership

Funds ownership: 0.85% [Q4 2023] → 0.53% (-0.32%) [Q1 2024]

2% less capital invested

Capital invested by funds: $1.8M [Q4 2023] → $1.77M (-$33.2K) [Q1 2024]

5% less funds holding

Funds holding: 22 [Q4 2023] → 21 (-1) [Q1 2024]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$72
10,187%
upside
Avg. target
$81
11,521%
upside
High target
$120
17,045%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
10,187%upside
$72
Buy
Reiterated
3 May 2024
HC Wainwright & Co.
Yi Chen
10,187%upside
$72
Buy
Reiterated
23 Apr 2024
HC Wainwright & Co.
Yi Chen
10,187%upside
$72
Buy
Reiterated
15 Apr 2024
HC Wainwright & Co.
Yi Chen
10,187%upside
$72
Buy
Maintained
18 Mar 2024
Piper Sandler
Edward Tenthoff
11,330%upside
$80
Overweight
Reiterated
13 Mar 2024

Financial journalist opinion